<DOC>
	<DOCNO>NCT00688636</DOCNO>
	<brief_summary>A randomized , placebo-controlled pilot study determine endoscopic recurrence Crohn 's disease 12 month curative , resective ileal ileocolonic surgery patient receive post-operative infliximab placebo</brief_summary>
	<brief_title>Infliximab Prevention Recurrent Crohn 's Disease After Surgery</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>men/women &gt; 18 year age curative resection/ileocolonic anastomosis Crohn 's disease may receive previously receive infliximab oral aminosalicylates corticosteroid , dose must stable 4 week prior surgery 6mercaptopurine , azathioprine methotrexate , individual must minimum 3 month prior surgery stable dose 4 week men woman must use adequate birth control duration study 6 month receive last infusion antibiotic treatment Crohn 's disease must discontinue within 12 week surgery ; antibiotic allowable throughout study long primary purpose antibiotic therapy primary treatment Crohn 's disease screening lab result must meet screening criterion ( hemoglobin = &gt; 8.5g/dL ; Serum glutamic oxaloacetic transaminase ,3 time upper normal limit , platelet =or &gt; 100 x 10 9th/L ; lymphocyte count =or &gt; 0.5 x 10 9th/L neutrophil =or &gt; 1.0 x 10 9th/L document negative reaction purify protein derivative skin test perform within 3 month prior baseline normal chest radiograph result within 3 month prior baseline capable provide write informed consent obtain prior conduct protocolspecified procedure willing adhere study visit schedule protocol requirement consider eligible accord tuberculosis eligibility assessment , screen early detection reactivation rule patient undergo resective surgery primary ileocolonic anastomosis temporary ileostomy upon takedown divert ileostomy . patient great 10 year Crohn 's disease require first resection short ( &lt; 10cm ) fibrostenotic stricture macroscopically active disease anastomosis time surgery presence stoma prior severe infusion reaction infliximab history anaphylaxis murine product chimeric protein follow medication take within 12 week surgery : cyclosporine , tacrolimus , sirolimus , mycophenolate mofetil , investigational drug , medication target reduce tumor necrosis factor positive stool culture enteric pathogen , pathogenic ovum parasite , Clostridium difficile toxin clinically significant sign enteric infection screen woman pregnant , nurse plan pregnancy trial within 6 month last infusion patient active tuberculosis , patient newly diagnose latent tuberculosis 's receive tuberculosis prophylaxis , patient recent close contact individual active tuberculosis opportunistic infection within 6 month screen chest radiograph within 3 month prior screen show malignancy , infection , abnormality suggestive tuberculosis documentation seropositive HIV documentation positive test hepatitis B surface antigen history document hepatitis C current signs/symptoms systemic lupus erythematosus , severe progressive , uncontrolled renal , hepatic , hematologic , gastrointestinal , endocrine , pulmonary , cardiac , neurologic cerebral disease presence transplant solid organ ( exception corneal transplant &gt; 3 month prior randomization ) Have current know malignancy history malignancy within 5 year screen ( except squamous basal cell carcinoma skin fully excise evidence recurrence ) history lymphoproliferative disease splenomegaly know substance abuse ( drug/alcohol ) /dependency within previous 3 year , history noncompliance medical regimen , condition may interfere adherence protocol requirement unwilling/unable undergo multiple venipuncture poor tolerability lack easy access know history demyelinate disease chronic recurrent infectious disease serious infection , hospitalization infection , treatment IV antibiotic infection within 2 month prior randomization serious concomitant illness may interfere participation trial concomitant diagnosis/history congestive heart failure current use prescription dos chronic/frequent use nonsteroidal antiinflammatory drug ulcerative colitis concurrent participation another investigative trial use investigational drug within 30 day prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>